PURA Announces New Research Report Recommending Speculative BUY And $0.25 PPS Target With Potential To $0.35
June 06 2019 - 8:32AM
InvestorsHub NewsWire
PURA Announces New Research Report
Recommending Speculative BUY And $0.25 PPS Target With Potential To
$0.35
DALLAS, TX -- June 6, 2019 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today announced that Goldman Small Cap Research
has released a new research report recommending PURA as a
Speculative BUY with a $0.25 PPS Target. Goldman Small Cap
Research further reports that the shares of PURA “have the
potential to reach the $0.35 mark.” The report highlights
PURA’s growing EVERx CBD Sports Water sales and the coming
introduction of new beverages as well as the potential for the
company to exceed its 2019 sales targets through the pending
doubling of its production capacity and through planned
acquisitions. The report further details recent updates
intended to accelerate the issue of Nouveau (USOTC:
NOUV) stock to PURA shareholders in a dividend distribution.
Notably, the report points to the capacity and quality
improvements enabled by the addition of a new team member with
exceptional beverage industry professional
experience.
Goldman Small Cap Research
Excerpt
“… a
series of company initiatives and industry events serve as
catalysts to drive PURA’s volume higher and the shares back to its
52-week high of $0.25. Depending upon the timing and magnitude of
the aforementioned events, we believe that these shares have the
potential to reach the $0.35 mark.”
See
Full Report:
PURA
Goldman Small Cap Research Report Including Analyst Credentials
& Disclosures
For
more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This
news release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024